EVO Stock Analysis: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$2.80
0.08 (2.94%)
▲
5d:
-0.36%
30d:
+2.94%
90d:
+15.7%
HOLD
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EVO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $2.80, which is considered fair relative to its 30-day fair value range of $2.73 to $3.00. From a valuation perspective, the stock is trading at a discount (Forward PE: -18.1) compared to its historical average (45.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVO is in a downtrend. Immediate support is located at $2.59, while resistance sits at $2.99.
Market Sentiment: EVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.19 (+85.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVO is in a downtrend. Immediate support is located at $2.59, while resistance sits at $2.99.
Market Sentiment: EVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.19 (+85.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.73 -
$3.00
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 85.5% below Wall St target ($5.19)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.73 -
$3.00
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.59
Resistance Level
$2.99
Current Trend
Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.06
Wall Street Target
$5.19
(+85.5%)
Revenue Growth (YoY)
-21.7%
Profit Margin
-26.0%
PE vs Historical
-18.1 vs 45.3
CHEAP
Share & Embed Analysis
Last updated: June 16, 2026 2:14 AM ET
Data refreshes hourly during market hours. Next update: 3:14 AM
Data refreshes hourly during market hours. Next update: 3:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 58 HOLD |
